US 11,744,890 B2
Saponin extraction
Ahmad Taimour Baig, Hamilton, MT (US); Juan Jose Diaz Garcia, Marietta, PA (US); Chad Austin Farrenburg, Hamilton, MT (US); Kent Raymond Myers, Hamilton, MT (US); Jeri Kay Sandvick, Hamilton, MT (US); and Jeb Yeatts Vandenburg, Hamilton, MT (US)
Assigned to GlaxoSmithKline Biologicals SA, Rixensart (BE)
Appl. No. 16/768,416
Filed by GLAXOSMITHKLINE BIOLOGICALS SA, Rixensart (BE)
PCT Filed Nov. 30, 2018, PCT No. PCT/EP2018/083233
§ 371(c)(1), (2) Date May 29, 2020,
PCT Pub. No. WO2019/106191, PCT Pub. Date Jun. 6, 2019.
Claims priority of provisional application 62/593,555, filed on Dec. 1, 2017.
Claims priority of application No. 17209796 (EP), filed on Dec. 21, 2017.
Prior Publication US 2020/0323980 A1, Oct. 15, 2020
Int. Cl. A61K 36/00 (2006.01); A61K 39/39 (2006.01); A61K 36/185 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/39 (2013.01) [A61K 36/185 (2013.01); A61K 2039/55577 (2013.01); A61K 2236/331 (2013.01)] 30 Claims
 
1. A crude aqueous extract of Quillaja saponaria Molina containing:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
1856 component:

OG Complex Work Unit Chemistry
and
2002 component:

OG Complex Work Unit Chemistry
(collectively referred to as QS-21 main peak components),
and 2018 component:

OG Complex Work Unit Chemistry
wherein the ratio of 2018 component/QS-21 main peak components is ≤0.075, as measured by UV absorbance at 214 nm, and wherein the crude aqueous extract comprises sodium benzoate.